批量新增 4 个讲座 - 2026-04-04 15:12 (#245)

Professor Shen is the academician of the Chinese Academy of Sciences, Qiushi Distinguished Professor at Zhejiang University, Dean of the College of Chemical and Biological Engineering, and Director of the Zhejiang Provincial Key Laboratory of Intelligent Biomaterials. He received his Bachelor of Science and Ph.D. from Zhejiang University and also a Ph.D. in Engineering from McMaster University. From 2002 to 2007, he served as Assistant Professor and then tenured Associate Professor at the University of Wyoming, USA. In 2008, he was invited to return to China and was awarded the National Science Fund for Distinguished Young Scholars. In 2014, he was appointed as a Chang Jiang Scholar Distinguished Professor by the Ministry of Education. He also serves as Executive Editor of Chem & Bioengineering published by the American Chemical Society and Deputy Director or Member of the Biomedical Polymers Subcommittee of the Chinese Society for Biomaterials. His research focuses on the synthesis of drug-delivering polymers and the mechanisms of drug delivery. He has proposed a new mechanism of tumor active delivery, known as TAEP, in which vector-induced cellular transcytosis enables active vascular extravasation and active intratumoral penetration. He has published over 600 SCI-indexed papers, been granted more than 41 patents in China & the United States and has been recognized as a Highly Cited Researcher worldwide. Three of his drug delivery systems have received five clinical trial approvals in China, the United States and South Korea. These systems are currently in Phase I/II clinical trials. As the principal investigator, he received the Second-Class National Natural Science Award in 2023.

## 讲座简介

Targeted drug delivery is a key strategy in cancer therapy, yet it faces the challenge of "many papers, few drugs." This dilemma stems from the low clinical efficacy of delivery systems, as well as difficulties in achieving controllable manufacturing and characterizing in vivo safety, which hinder clinical translation. Our team designs drug-delivering polymers with a focus on clinical translation. By analyzing the bottlenecks of conventional drug delivery, we uncovered a new mechanism of polymer-mediated transcytosis and established the TAEP retheory. This new paradigm overcomes the limitations of the traditional EPR effect and significantly improves delivery efficiency and therapeutic outcomes. We further proposed the concept of multipotent polymers, which greatly simplifies the structure and composition of delivery systems, thereby enhancing their manufacturability and safety characterization. We also developed new methods for the controllable synthesis of drug-delivering polymers, enabling precise control over their structure and function. Based on these advances, we established principles for the functional integration of delivery systems and developed strategies to modulate their nanoscale properties. These efforts have led to the creation of safe, efficient, and manufacturable drug delivery systems. Three nanomedicines based on these technologies have received five clinical trial authorizations and have been granted two orphan drug designations.

Targeted drug delivery is a key strategy in cancer therapy, yet it faces the challenge of 'many papers, few drugs.' This dilemma stems from the low clinical efficacy of delivery systems, as well as difficulties in achieving controllable manufacturing and characterizing in vivo safety, which hinder clinical translation. Our team designs drug-delivering polymers with a focus on clinical translation. By analyzing the bottlenecks of conventional drug delivery, we uncovered a new mechanism of polymer-mediated transcytosis and established the TAEP retheory. This new paradigm overcomes the limitations of the traditional EPR effect and significantly improves delivery efficiency and therapeutic outcomes. We further proposed the concept of multipotent polymers, which greatly simplifies the structure and composition of delivery systems, thereby enhancing their manufacturability and safety characterization. We also developed new methods for the controllable synthesis of drug-delivering polymers, enabling precise control over their structure and function. Based on these advances, we established principles for the functional integration of delivery systems and developed strategies to modulate their nanoscale properties. These efforts have led to the creation of safe, efficient, and manufacturable drug delivery systems. Three nanomedicines based on these technologies have received five clinical trial authorizations and have been granted two orphan drug designations.

## 海报链接

![](https://gtimg.liziwl.cn/post-img/2026-04-01T19-00-00_%E7%94%B3%E6%9C%89%E9%9D%92.jpg)

 No newline at end of file

* 地点：理学院一楼1142报告厅

## 主讲人简介

Professor Bin Liu is Tan Chin Tuan Centennial Professor at the National University of Singapore (NUS). Bin graduated with a bachelor’s degree from Nanjing University and a Ph.D. in Chemistry from NUS. She had postdoctoral training at the University of California, Santa Barbara before joining NUS in late 2005. Bin has been well-recognized for her contributions to polymer chemistry and organic nanomaterials for energy and biomedical applications. She is an international member of the US National Academy of Engineering. She served as the Deputy Editor to launch and develop ACS Materials Letters (2019-2024), a flagship materials journal of the American Chemical Society. She is now an associate editor for the Journal of the American Chemical Society.

刘斌教授是新加坡国立大学陈庆炎百年教授。刘斌本科毕业于南京大学，并于新加坡国立大学获得化学博士学位。在2005年底加入新加坡国立大学之前，她在加州大学圣塔芭芭拉分校进行了博士后培训。刘斌因其对高分子化学以及用于能源和生物医学应用的有机纳米材料的贡献而备受认可。她是美国国家工程院外籍院士。她曾作为副主编启动并发展了美国化学学会旗舰材料期刊《ACS Materials Letters》（2019-2024）。她现任《Journal of the American Chemical Society》副编辑。

## 讲座简介

The recent years have witnessed the fast grow of fluorogens with aggregation-induced emission characteristics (AIEgens) in biomedical research. The weak emission of AIEgens as molecular species and their bright luminescence as nanoscopic aggregates distinguish them from conventional organic luminophores and inorganic nanoparticles, making them wonderful candidates for many high-tech applications. In this talk, we report our recent discovery of AIEgens exhibiting high brightness and efficient reactive oxygen species generation in the aggregate state and further demonstrate their potential in image-guided cancer surgery and therapy. By integrating accurate material performance predictions from first-principles calculations with Bayesian optimization-based active learning, we developed a self-improving discovery system for high-performance photosensitizers, significantly accelerating materials innovation in biomedical research.

* 地点：理学院一楼化学系C1038报告厅

## 主讲人简介

唐波教授是中国科学院院士，崂山实验室首席科学家，教育部科学技术委员会委员，中国化学会会士，国家基础研究计划（973计划）首席科学家，国家杰出青年科学基金获得者，国家“百千万人才工程”入选者。他带领的教学科研团队入选首批“全国高校黄大年式教师团队”。唐教授的研究聚焦于生命健康的化学成像与传感、分析仪器开发、先进光刻胶和膜分离材料、环境自适应智能化学品以及海水制氢。他在 Nat. Synth., J. Am. Chem. Soc., Angew. Chem. Int. Ed. 和 Nat. Commun. 等期刊上发表过 500 多篇重要论文，作为通讯作者（包括共同通讯）或第一作者。他的论文被引用超过 59,000 次，H指数为 123。作为第一发明人，他持有 113 项授权国家发明专利，其中 11 项已转移，并获得了国家发明创业奖。他连续 11 年被列为爱思唯尔高被引中国研究者，并于 2024 年获得英国皇家化学会的 ChemComm 杰出贡献奖。作为项目负责人，他获得了一项国家自然科学奖二等奖和两项国家科学技术进步奖二等奖。他主持了多项国家级科研项目，包括国家基础研究计划（973 计划）、国家自然科学基金重点项目和国家重大科学仪器开发专项。

Professor Tang Bo is an academician of the Chinese Academy of Sciences, a Leading Scientist at Laoshan Laboratory, a member of the Science and Technology Commission of the Ministry of Education, a member of the Chemistry Teaching Steering Committee, a Fellow of the Chinese Chemical Society, a Chief Scientist of the National Basic Research Program (973 Program), a recipient of the National Science Fund for Distinguished Young Scholars, and a member of the National Hundred, Thousand and Ten Thousand Talents Program. He leads the teaching and research team that was selected as one of the first“National University Huang Danian-style Teacher Teams.” Professor Tang’s research focuses on chemical imaging and sensing for life and health, development of analytical instruments, advanced photoresist and membrane separation materials, environmentally adaptive intelligent chemicals, and seawater hydrogen production. He has published over 500 significant papers as corresponding author (including co-corresponding) or first author in journals such as Nat. Synth., J. Am. Chem. Soc., Angew. Chem. Int. Ed. and Nat. Commun. His papers have been cited more than 59,000 times, with an H-index of 123. As the first inventor, he holds 113 authorized national invention patents, 11 of which have been transferred, and has received the National Invention and Entrepreneurship Award. He has been consecutively named an Elsevier Highly Cited Chinese Researcher for 11 years, and in 2024 received the ChemComm Outstanding Contribution Award from the Royal Society of Chemistry. As the principal investigator, he has won one second prize of the National Natural Science Award and two second prizes of the National Science and Technology Progress Award. He has led a number of national-level research projects, including the National Basic Research Program (973 Program), key projects of the National Natural Science Foundation of China, and the National Major Scientific Research Instrument Development Project of the National Natural Science Foundation of China.

## 讲座简介

Interfaces serve as organizational hubs in living systems—from material exchange barriers in organs and tissues, to nodes for intercellular recognition and signal integration, to energy-converting platforms on organelle membranes, and ultimately to receptor–ligand interactions at the molecular level. Across this multiscale hierarchy, interfaces collectively dictate homeostasis, signal transduction, and metabolic coupling. Consequently, chemical sensing and imaging that span this full spectrum of interfaces—from organs to molecules—are essential not only for unraveling the mechanisms underlying health and disease, but also for establishing rational design principles in synthetic biology and enabling the construction of artificial biological systems. Advancing such methodologies hinges on leveraging the quantum properties of electrons and photons as a foundational underpinning, and on integrating multimodal techniques including super-resolution fluorescence imaging, photoacoustic imaging, magnetic resonance imaging, electrochemical imaging, and NV-center-based quantum sensing. By addressing key challenges such as the trade-off between penetration depth and resolution, the complexity of in vivo detection, and signal interference, this approach aims to establish a multiscale, multi-interface methodological framework that bridges microscopic quantum measurements with digital twin modeling, ultimately enabling precise regulation of life processes and rational design in synthetic biology.

卢柯，辽宁材料实验室主任，中国科学院金属研究所研究员。长期从事金属材料研究。主要贡献包括：在金属中发现了三种新型纳米结构：受限晶体 (Schwarz crystal) 结构，纳米孪晶结构，负能界面亚纳米结构。揭示了纳米孪晶强韧化和梯度纳米结构强韧化机制，发展了系列金属梯度纳米结构制备技术。提出利用稳定界面调控材料性能的“材料素化”策略，推动材料可持续发展。曾获 Acta Materialia 金质奖章、富兰克林·梅尔奖、德国洪堡研究奖、英国剑桥大学 Kelly 讲座人等荣誉。当选中国科学院院士 (2003)，德国国家科学院外籍院士 (2005)，美国工程院外籍院士 (2018)。入选国家高层次人才特殊支持计划首批杰出人才。

## 讲座简介

金属材料通常具有多晶结构，其内部由晶界(GBs)分隔的晶粒组成。晶界通过阻碍位错滑移实现金属强化，这一现象遵循经典的 Hall-Petch 关系。当晶粒细化至约 10 nm 时，金属强度可显著倍增。然而，由于晶界在热或力驱动条件下极易失稳，将晶粒进一步细化至该尺寸以下极具挑战，导致从纳米尺度到晶格极限之间的结构区间仍处于研究空白.<br/>近年来，通过对金属界面稳定化策略的深入研究，我们团队发现了一系列尺寸仅为数纳米的新型亚稳态多晶结构。本文重点介绍了两类“极限晶体”(Extreme Crystals)：(1) 具有低能界面特征的极限层状结构（如纳米孪晶结构以及具有负能界面的亚纳米结构）；(2) 具有三维周期性极小面(TPMS)晶界网络的极限纳米晶结构，即“受限晶体(Schwarz crystal)”。与常规纳米晶材料相比，极限晶体金属展现出更优异的稳定性和物理化学性能。本报告将系统探讨多种金属及合金体系中极限晶体的形成机制、结构特征、构效关系及发展前景。

金属材料通常具有多晶结构，其内部由晶界 (GBs) 分隔的晶粒组成。晶界通过阻碍位错滑移实现金属强化，这一现象遵循经典的 Hall-Petch 关系。当晶粒细化至约 10 nm 时，金属强度可显著倍增。然而，由于晶界在热或力驱动条件下极易失稳，将晶粒进一步细化至该尺寸以下极具挑战，导致从纳米尺度到晶格极限之间的结构区间仍处于研究空白。<br/> 近年来，通过对金属界面稳定化策略的深入研究，我们团队发现了一系列尺寸仅为数纳米的新型亚稳态多晶结构。本文重点介绍了两类 “极限晶体” (Extreme Crystals)：(1) 具有低能界面特征的极限层状结构（如纳米孪晶结构以及具有负能界面的亚纳米结构）；(2) 具有三维周期性极小面 (TPMS) 晶界网络的极限纳米晶结构，即“受限晶体 (Schwarz crystal)”。与常规纳米晶材料相比，极限晶体金属展现出更优异的稳定性和物理化学性能。本报告将系统探讨多种金属及合金体系中极限晶体的形成机制、结构特征、构效关系及发展前景。

## 海报链接

![](https://gtimg.liziwl.cn/post-img/2026-04-10T16-00-00_%E5%8D%A2%E6%9F%AF.jpg)

 No newline at end of file